How effective is dabrafenib?

Dabrafenib (Dabrafenib) is an anti-tumor drug used to treat non-small cell lung cancer and melanoma, with significant therapeutic effects. Combination therapy with the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib improved survival in patients with BRAF V600 mutated advanced melanoma.

In this double-blind, placebo-controlled, Phase 3 trial, we randomized 870 patients with completely resected stage III melanomaBRAF Patients with V600E or V600K mutations received oral dabrafenib (150 mg twice daily) and trimethinib (2 mg, once daily) (combination therapy, 438 patients) or two matching placebo tablets (432 patients) for 12 months. At a median follow-up of 2.8 years, the estimated 3-year recurrence-free survival rate in the combination arm58% and 39% in the placebo group (The hazard ratio for recurrence or death was 0.47 ; 95%Confidence interval[CI], 0.39to0.58;P<0.001). 3 in the combination treatment groupThe annual overall survival rate was 86% and 77% in the placebo group (The hazard ratio for death was 0.57; 95%The confidence interval was < span>0.42to0.79;P=0.0006), but this level of improvement did not exceed the prespecified interim analysis limitP=0.000019. The distant metastasis-free survival rate and recurrence-free rate in the combination treatment group were also higher than those in the placebo group. The safety profile of dabrafenib in combination with trimetinib was consistent with that observed with the combination in patients with metastatic melanoma.

In patients with BRAF V600E or V600K mutated III melanoma, adjuvant use of dabrafenib in combination with doxorubicinib resulted in a significantly lower risk of relapse than adjuvant placebo and was not associated with new toxic effects. If you want to get more high-quality information, you can contact Yaode , Yaode will do its best to learn more about high-quality overseas drugs for you.